Report : North America Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology [Molecular Diagnostics (Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, and Microarrays), Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology), Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)
At 9.1% CAGR, the North America Sepsis Diagnostics Market is speculated to be worth US$ 513.33 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America sepsis diagnostics market was valued at US$ 279.06 million in 2021 and is expected to reach US$ 513.33 million by 2028, registering an annual growth rate of 9.1% from 2021 to 2028. High incidence of sepsis due to increasing nosocomial infections and rise in demand for rapid diagnostic tests leading to increasing product launches are the critical factors attributed to the market expansion.
Infection is the root cause of sepsis. Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Among several types of infections, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. For instance, according to the "2020 National and State Healthcare-Associated Infections Progress Report", published by the Centers for Disease Control and Prevention (CDC) in 2021, about 24%, 35%, and 15% increase was recorded in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia, respectively, between 2019 and 2020 in the US. Additionally, as per a report published by the Global Sepsis Alliance (GSA), nearly 26 million people develop sepsis every year, and approximately 8 million patients die because of sepsis North America. Thus, the rising bloodstream infections will increase the adoption of sepsis diagnostic products. This is expected to drive the market during the forecast period.
On the contrary, lack of skilled professionals hurdles the growth of North America sepsis diagnostics market.
Based on product, the North America sepsis diagnostics market is divided into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held 43.2% market share in 2021, amassing US$ 120.54 million. It is projected to garner US$ 220.09 million by 2028 to expand at 9.0% CAGR during 2021–2028.
Based on technology, the North America sepsis diagnostics market is categorized into molecular diagnostics flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held 44.2% market share in 2021, amassing US$ 123.32 million. It is projected to garner US$ 222.64 million by 2028 to expand at 8.8% CAGR during 2021–2028. Further molecular diagnostics flow cytometry segment is further categorized into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, microarrays.
Based on Method, the North America sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held 66.0% market share in 2021, amassing US$ 184.07 million. It is projected to garner US$ 333.71 million by 2028 to expand at 8.9% CAGR during 2021–2028
Based on test type, the North America sepsis diagnostics market is divided into point-of-care tests and laboratory tests. The laboratory tests segment held 83.8% market share in 2021, amassing US$ 233.97 million. It is projected to garner US$ 428.51 million by 2028 to expand at 9.0% CAGR during 2021–2028
Based on pathogen, the North America sepsis diagnostics market is divided into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held 79.6% market share in 2021, amassing US$ 222.22 million. It is projected to garner US$ 414.70 million by 2028 to expand at 9.3% CAGR during 2021–2028
Based on end user, the North America sepsis diagnostics market is divided into hospitals, pathology and reference laboratories, and others. The hospitals segment held 47.3% market share in 2021, amassing US$ 132.01 million. It is projected to garner US$ 244.61 million by 2028 to expand at 9.3% CAGR during 2021–2028
Based on country, the North America sepsis diagnostics market has been categorised into the US, Canada, and Mexico. Our regional analysis states that US captured 82.3% market share in 2021. It was assessed at US$ 229.79 million in 2021 and is likely to hit US$ 424.35 million by 2028, exhibiting a CAGR of 9.2% during the forecast period.
Key players dominating the North America sepsis diagnostics market are Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; and T2 Biosystems, Inc. among others.
- In May 2021, Danaher has reaffirmed its commitment to Sepsis Alliance healthcare provider education programs. Danaher previously provided support for the Sepsis Alliance Clinical Community and the latest installment of the agreement.
- In Aug 2019, bioMérieux and Sepsis Alliance, the nation’s leading sepsis organization, renewed their collaboration to increase healthcare provider education on sepsis with the webinar series, Sepsis: Across the Continuum of Care. Together, bioMerieux and Sepsis Alliance have collaborated for five years in an effort to inform the public about the dangers and risk factors of sepsis and to promote clinical best-practices for early detection, diagnosis and treatment of the condition.
Contact Person: Sameer Joshi
Email Id: email@example.com